Hand eczema in US employees: a retrospective observational study of workers' compensation and medical claims [0.03%]
美国员工的手部湿疹：工人赔偿和医疗索赔的回顾性观察研究
Richard A Brook,Aseel Bin Sawad,Ian A Beren et al.
Richard A Brook et al.
Aims: This research quantified the impact of hand eczema (HE) on US employees. Methods: Retrospective observational analysis of real-wo...
Observational Study
Journal of medical economics. 2026 Dec;29(1):1164-1179. DOI:10.1080/13696998.2026.2656071 2026
Letter to the editor: five-year implant versus other contraception missing correct data [0.03%]
致编辑的信：五年植入式避孕棒与其他避孕方式比较数据有误
Sarah G Kirshner,Ciara E Hutchison,Mitchell D Creinin
Sarah G Kirshner
Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening [0.03%]
基于肺癌筛查提供戒烟服务的分布成本效果分析
H Fewster,P Nuttall,M Evison et al.
H Fewster et al.
Background: Lung cancer is a leading cause of cancer death, and smoking-related disease is a major cause of health inequality in England, driven by increased prevalence of smoking in deprived areas. Integrating smoking ce...
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer [0.03%]
奥希替尼联合铂类-培美曲塞与阿美替尼联合洛拉替尼一线治疗表皮生长因子受体突变型局部晚期或转移性非小细胞肺癌的成本比较
Gilberto de Lima Lopes,Harry Freeman,Emily Procter et al.
Gilberto de Lima Lopes et al.
Objectives: Novel first-line (1L) combination regimens offer improved efficacy for patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced or metastatic non-small cell lung cancer (NSCLC) versus th...
Comparative Study
Journal of medical economics. 2026 Dec;29(1):1059-1075. DOI:10.1080/13696998.2025.2609507 2026
Scott C Ratzan,Rebecca K Ivic,Kenneth H Rabin et al.
Scott C Ratzan et al.
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States [0.03%]
美国输血依赖型β地中海贫血患者使用exagamglogene autotemcel基因编辑疗法的成本效益分析
Chuka Udeze,Michael Gargano,Hongbo Yang et al.
Chuka Udeze et al.
Aims: Exagamglogene autotemcel (exa-cel) is a one-time nonviral gene-edited therapy approved in the United States (US) for treatment of patients aged ≥12 with transfusion-dependent β-thalassemia (TDT). Standard of care ...
Plain language summary looking at the impact of drug management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the USA [0.03%]
关于直接口服抗凝药对非瓣膜性房颤患者临床事件发生率和费用的影响：美国的用药管理策略简明概述
Rupesh Subash,Serina Deeba,Chloe Salter et al.
Rupesh Subash et al.
Changes in drug price reduction trends during Japan's transition to an annualized revision environment: a comparative analysis using open data from the national claims database [0.03%]
日本医保药物降价趋势的年度调整转型分析：基于全国理赔数据库公开数据的比较研究
Koichi Tsuda,Asuka Suzuki,Yoshinori Nakata
Koichi Tsuda
Objective: To address the lack of evidence on the effects of Japan's transition to an annualized revision environment, this study quantified the net change in drug price reduction rates between the biennial and annualized...
Comparative Study
Journal of medical economics. 2026 Dec;29(1):1076-1088. DOI:10.1080/13696998.2026.2651056 2026
Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison [0.03%]
帕博利珠单抗联合化疗治疗转移性非小细胞肺癌的成本效益：对照现实世界的数据进行直接比较的临床试验
Srinivas Teppala,Juhee Koo,Stephen Clarke et al.
Srinivas Teppala et al.
Objectives: Real-world evidence (RWE) is increasingly used in health technology assessment (HTA) to address uncertainties surrounding the generalizability of randomized clinical trial (RCT) data. Pembrolizumab plus platin...
Comparative Study
Journal of medical economics. 2026 Dec;29(1):1099-1110. DOI:10.1080/13696998.2026.2651038 2026